Latest Accentia Biopharmace (ABPI) Headlines
Post# of 7
Posted On: 03/08/2014 4:34:18 PM
Latest Accentia Biopharmace (ABPI) Headlines
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officers and Biovest International, Inc. - ABPI and BVTI
PR Newswire - Tue Aug 06, 4:26PM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc. ("Accentia" or the "Company") (Pink Sheets: ABPI) and certain of its officers and Biovest International, Inc. ("Biovest") (OTCQB: BVTI), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officers and Biovest International, Inc. - ABPI and BVTI
PR Newswire - Tue Aug 06, 4:26PM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc. ("Accentia" or the "Company") (Pink Sheets: ABPI) and certain of its officers and Biovest International, Inc. ("Biovest") (OTCQB: BVTI), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
(0)
(0)Accentia Biopharmaceuticals Inc (ABPI) Stock Research Links
Scroll down for more posts ▼